Name | Rofecoxib |
Synonyms | VIOXX MK-0966 ROFECOXIB Rofecoxid Rofecoxib Rofecoxib(Vioxx) Rofecoxib (MK0966) 4-[4-(Methylsulfonyl)phenyl]-3-phenyl- 4-[4-(MethylSLdfonyl)phenyl]-3-phenyl-2(5H)-furanone 4-[4-(methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one 4-[4-(Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone 4-[4-(Methylsulfonyl)-phenyl]-3-phenyl-2(5H)-furanone |
CAS | 162011-90-7 |
EINECS | 803-260-0 |
InChI | InChI=1/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3 |
Molecular Formula | C17H14O4S |
Molar Mass | 314.36 |
Density | 1.333±0.06 g/cm3(Predicted) |
Melting Point | 207°C |
Boling Point | 577.6±50.0 °C(Predicted) |
Flash Point | 303.1°C |
Water Solubility | 9mg/L(25 ºC) |
Solubility | Soluble in water (<1 mg/ml at 25 °C), DMSO (63 mg/ml at 25 °C), methanol (slightly) |
Vapor Presure | 2.42E-13mmHg at 25°C |
Appearance | off-white (pale yellow) crystalline powder |
Color | white to beige |
Merck | 14,8248 |
Storage Condition | 2-8°C |
Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months. |
Refractive Index | 1.619 |
Use | A selective Cox-2 inhibitor. |
In vitro study | Rofecoxib inhibits COX-2 dependent PGE2 production in human osteosarcoma cells with an IC50 of 26 nM. Rofecoxib is a purified time-dependent inhibitor of human recombinant COX-2 with an IC50 of 0.34 μm. Rofecoxib causes time-independent inhibition of purified human COX-1. Rofecoxib selectively inhibits lipopolysaccharide-induced, COX-derived PGE2 synthesis with an IC50 value of 0.53 μm in human whole blood assays, compared, inhibits the synthesis of COX-1 derived thromboxane B2 after blood coagulation with an IC50 value of 18.8 μm. Rofecoxib moderately inhibited phenacetin O-deethylation with an IC50 of 23 μm. Preincubation with microsomes and NADPH for 30 min significantly increased the inhibitory effect of Rofecoxib with an IC50 of 4.2 μm. The inactivation of CYP1A2 by Rofecoxib requires NADPH and is characterized by a K I of 4.8 μm. |
In vivo study | Rofecoxib effectively inhibited carrageenan-induced paw swelling, carrageenan-induced paw hyperalgesia, and lipopolysaccharide-induced fever with IC50 of 1.5 mg/kg,1.0 mg/kg, and 0.24 mg/kg, respectively. Rofecoxib also blocked adjuvant-induced arthritis with an IC50 of 0.74 mg/kg/day. In rats, Rofecoxib also has a protective effect against adjuvant-induced damage to cartilage and bone structures. Oral administration of Rofecoxib reduces portal pressure in rats treated with CCl4 for 8 weeks. In addition, rofecoxib administration reduced the number of activated HSCs and downregulated the liver protein levels of three detectable types of collagen, laminin, VEGF and CTGF in ccl4-treated rats. |
Hazard Symbols | Xn - Harmful |
Risk Codes | 22 - Harmful if swallowed |
WGK Germany | 3 |
RTECS | LU5135000 |
Reference Show more | 1. Liu Zhaoqing, Wanzhong, Jiang Zheng, Tuo Xun. Study on the interaction between rofecoxib and bovine serum albumin [J]. Journal of Analytical Science, 2020,36(03):421-426. 2. [IF = 4.098] Linlin Xu et al."Probing the interaction between levamlodipine and hemoglobin based on spectroscopic and molecular docking methods." Spectrochim Acta A. 2019 Dec;223:117306 |